
Roberto Moretto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1656387/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. Journal of the National Cancer Institute, 2022, 114, 271-279.	3.0	27
2	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. European Journal of Cancer, 2022, 165, 116-124.	1.3	6
3	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. Cancer Treatment Reviews, 2022, 106, 102382.	3.4	9
4	Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials. Cancers, 2022, 14, 52.	1.7	11
5	Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study. Clinical Cancer Research, 2022, 28, 2818-2829.	3.2	12
6	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2022, 23, 876-887.	5.1	83
7	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. British Journal of Cancer, 2022, 127, 957-967.	2.9	6
8	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. British Journal of Cancer, 2021, 124, 183-190.	2.9	7
9	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews, 2021, 92, 102135.	3.4	2
10	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	3.2	24
11	Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer. Future Oncology, 2021, 17, 1749-1759.	1.1	Ο
12	Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study Journal of Clinical Oncology, 2021, 39, e15566-e15566.	0.8	0
13	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Clinical Colorectal Cancer, 2021, 20, 314-317.	1.0	12
14	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. British Journal of Cancer, 2021, 125, 839-845.	2.9	9
15	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. European Journal of Cancer, 2021, 153, 16-26.	1.3	5
16	Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells. Investigational New Drugs, 2020, 38, 92-98.	1.2	3
17	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2020, 139, 81-89.	1.3	17
18	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. BMC Cancer, 2020, 20, 683.	1.1	53

Roberto Moretto

#	Article	IF	CITATIONS
19	Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?. Clinical Medicine Insights: Oncology, 2020, 14, 117955492094669.	0.6	9
20	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. British Journal of Cancer, 2020, 123, 403-409.	2.9	93
21	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer, 2020, 135, 78-88.	1.3	10
22	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 497-507.	5.1	196
23	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. Journal of Molecular Diagnostics, 2020, 22, 685-698.	1.2	11
24	Duration of oxaliplatinâ€based adjuvant chemotherapy in patients with Stage III or highâ€risk Stage II resected colon cancer. International Journal of Cancer, 2020, 146, 2652-2654.	2.3	3
25	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. Clinical Colorectal Cancer, 2020, 19, 191-199.e6.	1.0	20
26	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€~BRAF BeCool' study. European Journal of Cancer, 2019, 118, 121-130.	1.3	51
27	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. Clinical Colorectal Cancer, 2019, 18, 116-124.	1.0	7
28	BRAF mutant metastatic colorectal cancers: new arrows in our quiver. Annals of Translational Medicine, 2019, 7, S367-S367.	0.7	1
29	A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO) Journal of Clinical Oncology, 2019, 37, 3557-3557.	0.8	7
30	Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies Journal of Clinical Oncology, 2019, 37, 3534-3534.	0.8	0
31	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis Journal of Clinical Oncology, 2019, 37, 3540-3540.	0.8	Ο
32	<i>BRAF</i> V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. JAMA Surgery, 2018, 153, 1162.	2.2	0
33	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. ESMO Open, 2018, 3, e000403.	2.0	20
34	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. Colorectal Cancer, 2018, 7, CRC01.	0.8	3
35	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the "BRAF, BeCool―platform Journal of Clinical Oncology, 2018, 36, 639-639.	0.8	2
36	Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts) Journal of Clinical Oncology, 2018, 36, 675-675.	0.8	3

Roberto Moretto

#	Article	IF	CITATIONS
37	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget, 2018, 9, 7859-7866.	0.8	25
38	Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver limited metastatic colorectal cancer (mCRC) Journal of Clinical Oncology, 2018, 36, e15511-e15511.	0.8	0
39	The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness Journal of Clinical Oncology, 2018, 36, e15593-e15593.	0.8	0
40	Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients. , 2018, , .		0
41	Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation. , 2018, , .		3
42	First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm. Nature Reviews Clinical Oncology, 2017, 14, 113-113.	12.5	35
43	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. Oncologist, 2017, 22, 601-608.	1.9	108
44	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. Annals of Oncology, 2017, 28, iii94-iii95.	0.6	0
45	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. ESMO Open, 2017, 2, e000241.	2.0	10
46	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study Journal of Clinical Oncology, 2017, 35, 11508-11508.	0.8	1
47	Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group Journal of Clinical Oncology, 2017, 35, 3542-3542.	0.8	3
48	Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference Journal of Clinical Oncology, 2017, 35, 615-615.	0.8	1
49	Abstract LB-238: Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) inRASandBRAFwild-type (wt) metastatic colorectal cancer (mCRC). , 2017, , .		0
50	A still missing piece of the FIRE-3 puzzle. Lancet Oncology, The, 2016, 17, e515.	5.1	0
51	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. Oncologist, 2016, 21, 988-994.	1.9	94
52	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	2.9	56
53	Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients Journal of Clinical Oncology, 2016, 34, 3540-3540.	0.8	1
54	Genetic variants of <i>hENT-1</i> to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, 3580-3580.	0.8	2

ROBERTO MORETTO

#	Article	IF	CITATIONS
55	Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies Journal of Clinical Oncology, 2016, 34, e15054-e15054.	0.8	0
56	Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study Journal of Clinical Oncology, 2016, 34, TPS3627-TPS3627.	0.8	0
57	First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nature Reviews Clinical Oncology, 2015, 12, 607-619.	12.5	138
58	TAS-102 for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2015, 15, 1283-1292.	1.1	12
59	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. Radiotherapy and Oncology, 2015, 117, 315-321.	0.3	28
60	Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?. Clinical Colorectal Cancer, 2014, 13, 185-191.	1.0	23
61	Basaloid Squamous Cell Carcinoma: A Rare Tumor at the Esophagogastric Junction and an Unexpected Durable Complete Response to FOLFOX-4. Oncology Research and Treatment, 2014, 37, 55-58.	0.8	3
62	Bevacizumab maintenance in metastatic colorectal cancer: How long?. World Journal of Clinical Cases, 2014, 2, 717.	0.3	0
63	Risk factors for cancer-related venous thromboembolism in ambulatory patients Journal of Clinical Oncology, 2014, 32, e20625-e20625.	0.8	0
64	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. Anti-Cancer Drugs, 2013, 24, 980-985.	0.7	19
65	Tumor-to-tumor metastasis. Anti-Cancer Drugs, 2013, 24, 759-764.	0.7	5
66	Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion of etiopathogenesis and diagnostic tools. International Journal of Hematology, 2012, 95, 320-323.	0.7	8